COSTA MESA, Calif.--(EON: Enhanced Online News)--Cerebain Biotech Corp. (“Cerebain” or “Company”) (OTCQB: CBBT), a development-stage medical device company focused on the creation and clinical development of a minimally invasive implantable device to address dementias, and in particular, Alzheimer’s disease, today announced that the Company has engaged NMS Capital Advisors, LLC (“NMS”) as its financial advisor.
“We are very excited to be working with Cerebain on their capital markets and business expansion needs as well as an advisor to the management team. The work they are doing is very important in the fight to effectively treat Alzheimer’s disease.”
Founded in 2006 and headquartered in Beverly Hills, California, NMS is a leading global focused investment banking and advisory firm providing an array of Global Capital Advisory™ services which include M&A, Investment Banking, Corporate Finance and Strategic Advisory services to both public and private clients located in the United States, Asia and Europe. NMS’ Investment Banking consists of seasoned professionals with in-depth domestic and international capital markets transaction experience. NMS has been consistently listed among the Top Investment Banks and Securities Brokerage Firms by the Los Angeles Business Journal (LABJ) since 2014.
Trevor M. Saliba, Chairman and CEO of NMS Capital Advisors, said, “We are very excited to be working with Cerebain on their capital markets and business expansion needs as well as an advisor to the management team. The work they are doing is very important in the fight to effectively treat Alzheimer’s disease.”
NMS will be working with the Company’s senior management on the Company’s strategic growth and business plan, including capital raising, potential strategic acquisitions, various financing strategies and its current capitalization plan.
About Cerebain Biotech Corp.
Cerebain Biotech (OTCQB: CBBT) is a development-stage medical device company focused on the creation and clinical development of a minimally invasive implantable device and a synthetic drug solution. The device leverages the clinically observable, positive impact that omentum stimulation has on cognitive function as related to dementias, and in particular, Alzheimer’s disease. The corporate vision is based on these positive clinical observations. Visit us at www.cerebain.com or connect with us on Twitter and Facebook to learn more.
About NMS Capital Advisors
Founded in 2006, NMS Capital Advisors, LLC is a leading full service, global focused investment banking, securities and wealth management firm headquartered in Beverly Hills, California. We provide a full array of investment banking and advisory services including debt and equity capital raising for public and private companies, mergers and acquisitions, cross-border advisory, private equity and hedge fund advisory, valuations and fairness opinions, EB-5 capital advisory, securities brokerage and other strategic advisory services. Together with our affiliated registered investment advisory firm, NMS Capital Asset Management, Inc. we offer wealth management, alternative investments, insurance and asset management services. NMS Capital Advisors is registered broker-dealer with the Securities and Exchange Commission.
This news release contains certain "forward-looking statements." Forward-looking statements are based on current expectations and assumptions and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and many of which are beyond the Company's control. The forward-looking statements are also identified through the use of words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict" "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from these forward-looking statements as a result of a number of risk factors detailed in the Company's reports filed with OTC Markets. Given these risks and uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements and no assurances can be given that such statements will be achieved.